Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.
2.

Molecular Dynamics Analysis of Binding of Kinase Inhibitors to WT EGFR and the T790M Mutant.

Park J, McDonald JJ, Petter RC, Houk KN.

J Chem Theory Comput. 2016 Apr 12;12(4):2066-78. doi: 10.1021/acs.jctc.5b01221. Epub 2016 Apr 4.

PMID:
27010480
3.

CNS Anticancer Drug Discovery and Development Conference White Paper.

Levin VA, Tonge PJ, Gallo JM, Birtwistle MR, Dar AC, Iavarone A, Paddison PJ, Heffron TP, Elmquist WF, Lachowicz JE, Johnson TW, White FM, Sul J, Smith QR, Shen W, Sarkaria JN, Samala R, Wen PY, Berry DA, Petter RC.

Neuro Oncol. 2015 Nov;17 Suppl 6:vi1-26. doi: 10.1093/neuonc/nov169.

4.

In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing.

Tjin Tham Sjin R, Lee K, Walter AO, Dubrovskiy A, Sheets M, Martin TS, Labenski MT, Zhu Z, Tester R, Karp R, Medikonda A, Chaturvedi P, Ren Y, Haringsma H, Etter J, Raponi M, Simmons AD, Harding TC, Niu D, Nacht M, Westlin WF, Petter RC, Allen A, Singh J.

Mol Cancer Ther. 2014 Jun;13(6):1468-79. doi: 10.1158/1535-7163.MCT-13-0966. Epub 2014 Apr 10.

5.

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, Sheets M, St Martin T, Karp R, van Kalken D, Chaturvedi P, Niu D, Nacht M, Petter RC, Westlin W, Lin K, Jaw-Tsai S, Raponi M, Van Dyke T, Etter J, Weaver Z, Pao W, Singh J, Simmons AD, Harding TC, Allen A.

Cancer Discov. 2013 Dec;3(12):1404-15. doi: 10.1158/2159-8290.CD-13-0314. Epub 2013 Sep 24.

6.

Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans.

Evans EK, Tester R, Aslanian S, Karp R, Sheets M, Labenski MT, Witowski SR, Lounsbury H, Chaturvedi P, Mazdiyasni H, Zhu Z, Nacht M, Freed MI, Petter RC, Dubrovskiy A, Singh J, Westlin WF.

J Pharmacol Exp Ther. 2013 Aug;346(2):219-28. doi: 10.1124/jpet.113.203489. Epub 2013 May 24.

PMID:
23709115
7.

Leukaemia update. Part 2: managing patients with leukaemia in the community.

Grigoropoulos NF, Petter R, Van 't Veer MB, Scott MA, Follows GA.

BMJ. 2013 Apr 9;346:f1932. doi: 10.1136/bmj.f1932. Review. No abstract available.

PMID:
23571739
8.

Leukaemia update. Part 1: diagnosis and management.

Grigoropoulos NF, Petter R, Van 't Veer MB, Scott MA, Follows GA.

BMJ. 2013 Mar 28;346:f1660. doi: 10.1136/bmj.f1660. Review. No abstract available.

PMID:
23538920
9.

Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα.

Nacht M, Qiao L, Sheets MP, St Martin T, Labenski M, Mazdiyasni H, Karp R, Zhu Z, Chaturvedi P, Bhavsar D, Niu D, Westlin W, Petter RC, Medikonda AP, Singh J.

J Med Chem. 2013 Feb 14;56(3):712-21. doi: 10.1021/jm3008745. Epub 2013 Feb 5.

PMID:
23360348
10.
11.

The resurgence of covalent drugs.

Singh J, Petter RC, Baillie TA, Whitty A.

Nat Rev Drug Discov. 2011 Apr;10(4):307-17. doi: 10.1038/nrd3410. Review.

PMID:
21455239
12.

Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine.

Hagel M, Niu D, St Martin T, Sheets MP, Qiao L, Bernard H, Karp RM, Zhu Z, Labenski MT, Chaturvedi P, Nacht M, Westlin WF, Petter RC, Singh J.

Nat Chem Biol. 2011 Jan;7(1):22-4. doi: 10.1038/nchembio.492. Epub 2010 Nov 28.

PMID:
21113170
13.

Targeted covalent drugs of the kinase family.

Singh J, Petter RC, Kluge AF.

Curr Opin Chem Biol. 2010 Aug;14(4):475-80. doi: 10.1016/j.cbpa.2010.06.168. Epub 2010 Jul 6.

PMID:
20609616
14.

Acylating drugs: redesigning natural covalent inhibitors.

Kluge AF, Petter RC.

Curr Opin Chem Biol. 2010 Jun;14(3):421-7. doi: 10.1016/j.cbpa.2010.03.035. Epub 2010 Apr 24. Review.

PMID:
20457000
15.

Tricyclic imidazoline derivatives as potent and selective adenosine A1 receptor antagonists.

Vu CB, Kiesman WF, Conlon PR, Lin KC, Tam M, Petter RC, Smits G, Lutterodt F, Jin X, Chen L, Zhang J.

J Med Chem. 2006 Nov 30;49(24):7132-9.

PMID:
17125265
16.

Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists.

Kiesman WF, Zhao J, Conlon PR, Dowling JE, Petter RC, Lutterodt F, Jin X, Smits G, Fure M, Jayaraj A, Kim J, Sullivan G, Linden J.

J Med Chem. 2006 Nov 30;49(24):7119-31.

PMID:
17125264
17.

Norbornyllactone-substituted xanthines as adenosine A(1) receptor antagonists.

Kiesman WF, Zhao J, Conlon PR, Petter RC, Jin X, Smits G, Lutterodt F, Sullivan GW, Linden J.

Bioorg Med Chem. 2006 Jun 1;14(11):3654-61. Epub 2006 Feb 2.

PMID:
16458010
18.

N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.

Baker DP, Lin EY, Lin K, Pellegrini M, Petter RC, Chen LL, Arduini RM, Brickelmaier M, Wen D, Hess DM, Chen L, Grant D, Whitty A, Gill A, Lindner DJ, Pepinsky RB.

Bioconjug Chem. 2006 Jan-Feb;17(1):179-88.

PMID:
16417267
19.

Synthesis of [1,2,4]triazolo[1,5-a]pyrazines as adenosine A2A receptor antagonists.

Dowling JE, Vessels JT, Haque S, Chang HX, van Vloten K, Kumaravel G, Engber T, Jin X, Phadke D, Wang J, Ayyub E, Petter RC.

Bioorg Med Chem Lett. 2005 Nov 1;15(21):4809-13.

PMID:
16153830
20.

Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.

Vu CB, Pan D, Peng B, Kumaravel G, Smits G, Jin X, Phadke D, Engber T, Huang C, Reilly J, Tam S, Grant D, Hetu G, Petter RC.

J Med Chem. 2005 Mar 24;48(6):2009-18.

PMID:
15771443
21.

Synthesis of alkyne derivatives of a novel triazolopyrazine as A(2A) adenosine receptor antagonists.

Yao G, Haque S, Sha L, Kumaravel G, Wang J, Engber TM, Whalley ET, Conlon PR, Chang H, Kiesman WF, Petter RC.

Bioorg Med Chem Lett. 2005 Feb 1;15(3):511-5.

PMID:
15664803
22.

Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists.

Peng H, Kumaravel G, Yao G, Sha L, Wang J, Van Vlijmen H, Bohnert T, Huang C, Vu CB, Ensinger CL, Chang H, Engber TM, Whalley ET, Petter RC.

J Med Chem. 2004 Dec 2;47(25):6218-29.

PMID:
15566292
23.

Rational design of potent and selective VLA-4 inhibitors and their utility in the treatment of asthma.

Singh J, Adams S, Carter MB, Cuervo H, Lee WC, Lobb RR, Pepinsky RB, Petter R, Scott D.

Curr Top Med Chem. 2004;4(14):1497-507. Review.

PMID:
15544540
24.

Design, synthesis, and analysis of a polyethelene glycol-modified (PEGylated) small molecule inhibitor of integrin {alpha}4{beta}1 with improved pharmaceutical properties.

Pepinsky RB, Lee WC, Cornebise M, Gill A, Wortham K, Chen LL, Leone DR, Giza K, Dolinski BM, Perper S, Nickerson-Nutter C, Lepage D, Chakraborty A, Whalley ET, Petter RC, Adams SP, Lobb RR, Scott DM.

J Pharmacol Exp Ther. 2005 Feb;312(2):742-50. Epub 2004 Oct 14.

PMID:
15485895
25.

Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists.

Vu CB, Shields P, Peng B, Kumaravel G, Jin X, Phadke D, Wang J, Engber T, Ayyub E, Petter RC.

Bioorg Med Chem Lett. 2004 Oct 4;14(19):4835-8.

PMID:
15341934
26.

Studies on adenosine A2a receptor antagonists: comparison of three core heterocycles.

Vu CB, Pan D, Peng B, Sha L, Kumaravel G, Jin X, Phadke D, Engber T, Huang C, Reilly J, Tam S, Petter RC.

Bioorg Med Chem Lett. 2004 Oct 4;14(19):4831-4.

PMID:
15341933
27.

Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.

Vu CB, Peng B, Kumaravel G, Smits G, Jin X, Phadke D, Engber T, Huang C, Reilly J, Tam S, Grant D, Hetu G, Chen L, Zhang J, Petter RC.

J Med Chem. 2004 Aug 12;47(17):4291-9.

PMID:
15294001
28.

An assessment of the mechanistic differences between two integrin alpha 4 beta 1 inhibitors, the monoclonal antibody TA-2 and the small molecule BIO5192, in rat experimental autoimmune encephalomyelitis.

Leone DR, Giza K, Gill A, Dolinski BM, Yang W, Perper S, Scott DM, Lee WC, Cornebise M, Wortham K, Nickerson-Nutter C, Chen LL, LePage D, Spell JC, Whalley ET, Petter RC, Adams SP, Lobb RR, Pepinsky RB.

J Pharmacol Exp Ther. 2003 Jun;305(3):1150-62. Epub 2003 Mar 6.

PMID:
12626659
29.

Preparation of 8-substituted xanthine CVT-124 precursor by late stage pyrimidine ring closure.

Herr RJ, Vogt PF, Meckler H, Trova MP, Schow SR, Petter RC.

J Org Chem. 2002 Jan 11;67(1):188-93.

PMID:
11777458
30.

A survey of heterobasidiomycetous yeasts for the presence of the genes homologous to virulence factors of Filobasidiella neoformans, CNLAC1 and CAP59.

Petter R, Kang BS, Boekhout T, Davis BJ, Kwon-Chung KJ.

Microbiology. 2001 Aug;147(Pt 8):2029-36.

PMID:
11495981
31.

Evidence that ligand and metal ion binding to integrin alpha 4beta 1 are regulated through a coupled equilibrium.

Chen LL, Whitty A, Scott D, Lee WC, Cornebise M, Adams SP, Petter RC, Lobb RR, Pepinsky RB.

J Biol Chem. 2001 Sep 28;276(39):36520-9. Epub 2001 Jul 25.

32.

On-resin macrocyclization of peptides via intramolecular SnAr reactions.

Fotsch C, Kumaravel G, Sharma SK, Wu AD, Gounarides JS, Nirmala NR, Petter RC.

Bioorg Med Chem Lett. 1999 Aug 2;9(15):2125-30.

PMID:
10465530
33.

Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans.

Mondon P, Petter R, Amalfitano G, Luzzati R, Concia E, Polacheck I, Kwon-Chung KJ.

Antimicrob Agents Chemother. 1999 Aug;43(8):1856-61.

34.

Regulation of expression of ribosomal protein L-21 genes of Entamoeba histolytica and E. dispar is at the post-transcriptional level.

Moshitch-Moshkovitch S, Petter R, Levitan A, Stolarsky T, Mirelman D.

Mol Microbiol. 1998 Feb;27(4):677-85.

35.
36.

Upstream regions of rp L21 genes play a role in regulation of expression at the post-transcriptional level in E. histolytica and E. dispar.

Moshitch-Moshkovitch S, Stolarsky T, Petter R, Mirelman D.

Arch Med Res. 1997;28 Spec No:36-8. No abstract available.

PMID:
9033004
37.

Genomic variation in C. albicans.

Wickes BL, Petter R.

Curr Top Med Mycol. 1996 Dec;7(1):71-86. Review.

PMID:
9504060
38.
39.

Characterization of two distinct gene transcripts for ribosomal protein L21 from pathogenic and nonpathogenic strains of Entamoeba histolytica.

Petter R, Moshitch S, Rozenblatt S, Nuchamowitz Y, Mirelman D.

Gene. 1994 Dec 2;150(1):181-6.

PMID:
7959049
40.

Electrophoretic karyotype and chromosome assignments for a pathogenic and a nonpathogenic strain of Entamoeba histolytica.

Petter R, Rozenblatt S, Schechtman D, Wellems TE, Mirelman D.

Infect Immun. 1993 Aug;61(8):3574-7.

41.

Linkage between actin and ribosomal protein L21 genes in Entamoeba histolytica.

Petter R, Rozenblatt S, Nuchamowitz Y, Mirelman D.

Mol Biochem Parasitol. 1992 Dec;56(2):329-33. No abstract available.

PMID:
1484554
42.

Chromosome walk in Entamoeba histolytica: the gene encoding for ribosomal protein L21 neighbors one of the actin genes.

Petter R, Rozenblatt S, Nuchamowitz Y, Mirelman D.

Arch Med Res. 1992;23(2):45-8.

PMID:
1340321
43.

Intergeneric conjugation between Escherichia coli and Streptomyces species.

Mazodier P, Petter R, Thompson C.

J Bacteriol. 1989 Jun;171(6):3583-5.

44.

Catalytic hydrolysis of a phosphate triester by tetracoordinated zinc complexes.

Gellman SH, Petter R, Breslow R.

J Am Chem Soc. 1986 Apr 1;108(9):2388-94. doi: 10.1021/ja00269a041. No abstract available.

PMID:
22175588

Supplemental Content

Loading ...
Support Center